PRKN and ovarian carcinoma: Previous studies demonstrated that PINK1/Parkin dependent mitophagy can facilitate chemotherapy resistance in ovarian cancer (32), hepatic carcinoma (33, 34), breast adenocarcinoma (35) and lung cancer (36).